Skip to Main Content

INFORMATION FOR

    Immune System, Phase III

    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

    What is the purpose of this trial?

    To evaluate the long-term safety and tolerability of seladelpar.

    • Trial with
      CymaBay Therapeutics, Inc.
    • Ages
      18 years - 75 years
    • Gender
      Both

    Contact Information

    For more information about this study, including how to volunteer, contact Suzie Christopher

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

    • Last Updated
      07/23/2024
    • Study HIC
      #2000030598